Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07093931, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
Histologically confirmed HER2 positive ( human epidermal growth factor receptor 2 [ HER2 ] positive, estrogen receptor [ ER ] and progesterone receptor [ PR ] negative or positive );
Inclusion criterion 4
Stage at presentation: T1c N1-2 or T2-4 N0-2;
Inclusion criterion 5
Provides tumor tissue specimen to assess tumor programmed death-ligand 1 (PD-L1); .For women of childbearing potential: agreement to use contraceptive methods. Women who are not postmenopausal or have undergone a sterilization procedure must have a negative serum pregnancy test result within 72 hours prior to initiation of study drug.
Inclusion criterion 18
patients who received chemotherapy, endocrine therapy, immunotherapy, biotherapy or TACE within 4 weeks before admission
Exclusion criterion 3
Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment
Exclusion criterion 4
Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies .Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
Exclusion criterion 5
Major surgical procedure within 4 weeks prior to initiation of study treatment
Exclusion criterion 6
Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment
Exclusion criterion 12
Has evidence of active tuberculosis within 1year prior to initiation of study treatment
Exclusion criterion 13
Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment
Exclusion criterion 17
Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment
Exclusion criterion 18
Neutrophils ≥ 1.5×10\^9/L
Inclusion criterion 7
Platelets ≥ 100×10\^9/L
Inclusion criterion 8
Hemoglobin ≥ 90g/L
Inclusion criterion 9
Total bilirubin≤ 1.5 × the upper limit of normal (ULN)
Inclusion criterion 11
ALT and AST ≤ 3 × ULN
Inclusion criterion 12
ALP≤ 2.5 × ULN
Inclusion criterion 13
BUN and Cr ≤ 1.5 × ULN
Inclusion criterion 14
TSH≤ ULN
Inclusion criterion 15
at least one measurable lesion according to RECIST 1.1;
Inclusion criterion 6
Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study .Has a known history of Human Immunodeficiency Virus (HIV).
Exclusion criterion 9
Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial .History of neurological or psychiatric disorders, including epilepsy or dementia.
Exclusion criterion 20
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07093931, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Newly diagnosed breast cancer
- 18-70 Years, female;
- life expectancy is not less than 3 months
- Histologically confirmed HER2 positive ( human epidermal growth factor receptor 2 [ HER2 ] positive, estrogen receptor [ ER ] and progesterone receptor [ PR ] negative or positive );
- Stage at presentation: T1c N1-2 or T2-4 N0-2;
- at least one measurable lesion according to RECIST 1.1;
Adequate function of major organs meets the following requirements:
- Neutrophils ≥ 1.5×10\^9/L
- Platelets ≥ 100×10\^9/L
- Hemoglobin ≥ 90g/L
- lymphocyte≥0.5×10\^9/L
- Total bilirubin≤ 1.5 × the upper limit of normal (ULN)
- ALT and AST ≤ 3 × ULN
- ALP≤ 2.5 × ULN
- BUN and Cr ≤ 1.5 × ULN
- TSH≤ ULN
- Left ventricular ejection fraction (LVEF) ≥ 50%
- QTcF ≤ 470 ms
- Provides tumor tissue specimen to assess tumor programmed death-ligand 1 (PD-L1); .For women of childbearing potential: agreement to use contraceptive methods. Women who are not postmenopausal or have undergone a sterilization procedure must have a negative serum pregnancy test result within 72 hours prior to initiation of study drug.
Exclusion Criteria:
- Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer
- Inflammatory breast cancer
- patients who received chemotherapy, endocrine therapy, immunotherapy, biotherapy or TACE within 4 weeks before admission
- Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment
- Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies .Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
- Major surgical procedure within 4 weeks prior to initiation of study treatment
- Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus
- Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases
- Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study .Has a known history of Human Immunodeficiency Virus (HIV).
- Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis
- Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
- Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment
- Has evidence of active tuberculosis within 1year prior to initiation of study treatment
- Prior allogeneic stem cell or solid organ transplantation
- Pre-existing motor or sensory neuropathy of a severity≥grade 2
- Has significant cardiovascular disease
- Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment
- Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment
- Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial .History of neurological or psychiatric disorders, including epilepsy or dementia.
- any other situation evaluated by researchers
Quoted from ClinicalTrials.gov, NCT07093931, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07093931, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.